13% business increase for Iasi-based Antibiotice

Iasi-based local producer Antibiotice posted a turnover worth some 37 million euros in the first nine months of the year, a 12.8% increase against the corresponding period of last year. During the same period, company profit amounted to 5.4 million euros, a 12.7% increase against the first nine months of last year. “We saw the increases in turnover and profit that we were expecting. By the end of the year we intend to see a 24% advance in turnover, and after nine months we are on schedule,” Ioan Nani, general manager of the drug producer told ZF. Nani added that growth witnessed by Antibiotice during this period exceeded the market growth trend. “The company’s market share rose from 3.17%, to 3.3% over the first three quarters of last year. Which brings us increasingly closer to our end of year target of 3.5%,” continued Ioan Nani. The drug market could increase by up to 30% this year, according to players in the industry. “This year has seen many changes on the market. We consolidated our position on the hospital segment. Antibiotice is a maker of injectable drugs, and hospitals are the only segment where we can achieve consolidation,” says the Antibiotice representative.